IO Biotech, Inc. (IOBT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
IO Biotech, Inc. (IOBT) trades at $0.01 with AI Score 49/100 (Grade C). IO Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing immune-modulating cancer therapies. Market cap: $885,690, Sector: Healthcare.
Price live · AI analysis from May 9, 2026IOBT stock analysis for 2026: Analysts have set a consensus price target of $0.50 for IO Biotech, Inc., suggesting 3961.7% upside from the current price of $0.01. The AI MoonshotScore is 49/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
IOBT: the 1 perspectives are evenly split.
How is this calculated? →IO Biotech, Inc. (IOBT) Healthcare & Pipeline Overview
IO Biotech, Inc. is a clinical-stage biopharmaceutical company leveraging its T-win technology platform to develop immune-modulating cancer therapies. Their lead candidate, IO102-IO103, targets immunosuppressive proteins and is currently in Phase 2 trials for melanoma and Phase 1 trials for other cancers, positioning them in the competitive immunotherapy landscape.
What Is the Investment Thesis for IOBT?
IO Biotech operates in the high-growth cancer immunotherapy market, with its T-win platform representing a novel approach to modulating the tumor microenvironment. The lead candidate, IO102-IO103, currently in Phase 2 trials for melanoma, presents a near-term value driver if clinical results are positive. Success in ongoing Phase 1 trials for other cancers could further expand the potential market. The company's focus on targeting multiple immunosuppressive pathways, such as IDO and PD-L1, differentiates it from competitors focusing on single targets. However, as a clinical-stage company with a market cap of 886K, IO Biotech faces significant clinical and regulatory risks. The biotechnology sector is competitive, and the success of IO Biotech hinges on the clinical trial outcomes and subsequent regulatory approvals of its product candidates.
Based on FMP financials and quantitative analysis
IOBT Key Highlights
- IO102-IO103 is in Phase 2 clinical trials for melanoma, representing a key potential value inflection point.
- IO102-IO103 is also in Phase 1 clinical trials for lung, head and neck, bladder, and melanoma cancer, expanding its potential applications.
- The T-win technology platform targets immunosuppressive proteins, offering a differentiated approach in cancer immunotherapy.
- IO Biotech is developing IO112, targeting Arginase 1, to further enhance the immune response against tumors.
- The company is based in Copenhagen, Denmark, providing access to European markets and talent.
Who Are IOBT's Competitors?
IOBT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRNA Moderna, Inc. | $81.80 | +2.56% | 33B | — |
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| PFE Pfizer Inc. | $23.73 | -2.43% | $135.25B | 64 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IOBT's Key Strengths?
- Novel T-win technology platform.
- Pipeline of immune-modulating cancer therapies.
- Focus on targeting the tumor microenvironment.
- Experienced management team.
What Are IOBT's Weaknesses?
- Clinical-stage company with no approved products.
- Reliance on clinical trial success.
- Limited financial resources.
- High risk of clinical trial failure.
What Could Drive IOBT Stock Higher?
- Phase 2 clinical trial results for IO102-IO103 in melanoma.
- Phase 1 clinical trial results for IO102-IO103 in lung, head and neck, bladder, and melanoma cancer.
- Advancement of IO112 through clinical development.
- Potential strategic partnerships and collaborations.
What Are the Key Risks for IOBT?
- Financial-distress signal — its Altman Z-Score of -21.30 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for IO102-IO103 or IO112.
- Regulatory hurdles and approval delays.
- Competition from established pharmaceutical companies.
- Limited financial resources.
- Changes in the healthcare landscape.
What Are the Growth Opportunities for IOBT?
- Expansion of IO102-IO103 into additional cancer indications: Positive results from ongoing Phase 1 trials for lung, head and neck, bladder, and melanoma cancer could lead to the expansion of IO102-IO103 into these additional indications. Each of these indications represents a significant market opportunity, potentially increasing the addressable patient population and revenue potential for IO Biotech. The timeline for this expansion depends on the successful completion of clinical trials and regulatory approvals.
- Advancement of IO112 through clinical development: IO112, targeting Arginase 1, represents another growth opportunity for IO Biotech. Successful preclinical and clinical development of IO112 could lead to a new product offering and further validate the T-win technology platform. The market for Arginase 1-targeted therapies is emerging, and IO Biotech could be among the first to market with a novel therapy. The timeline for this development depends on preclinical and clinical trial progress.
- Strategic partnerships and collaborations: IO Biotech could pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships could provide access to additional funding, expertise, and resources, enabling IO Biotech to expand its reach and impact. The timing and nature of these partnerships are uncertain but could significantly impact the company's growth trajectory.
- Expansion into new geographic markets: While currently based in Denmark, IO Biotech could expand its operations into new geographic markets, such as the United States and Asia, to access larger patient populations and commercial opportunities. This expansion could involve establishing new offices, conducting clinical trials in these regions, and building relationships with local healthcare providers and regulatory agencies. The timeline for this expansion depends on the company's strategic priorities and available resources.
- Development of new product candidates based on the T-win platform: IO Biotech could leverage its T-win technology platform to develop new product candidates targeting other immunosuppressive mechanisms in the tumor microenvironment. This could lead to a pipeline of novel cancer therapies and further differentiate the company from its competitors. The timeline for this development depends on research and development efforts and available funding.
What Opportunities Does IOBT Have?
- Expansion into new cancer indications.
- Strategic partnerships with larger pharmaceutical companies.
- Advancement of IO112 through clinical development.
- Development of new product candidates based on the T-win platform.
What Threats Does IOBT Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and approval delays.
- Clinical trial failures.
- Changes in the healthcare landscape.
What Are IOBT's Competitive Advantages?
- Proprietary T-win technology platform.
- Pipeline of novel immune-modulating cancer therapies.
- Focus on targeting the tumor microenvironment.
- Intellectual property protection for its product candidates.
What Does IOBT Do?
IO Biotech, Inc., founded in 2014 and based in Copenhagen, Denmark, is a clinical-stage biopharmaceutical company dedicated to developing innovative immune-modulating cancer therapies. The company's core technology, the T-win platform, is designed to target and neutralize immunosuppressive mechanisms within the tumor microenvironment, thereby enhancing the body's natural ability to fight cancer. Their lead product candidate, IO102-IO103, is a dual-target therapy designed to counteract the effects of Indoleamine 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1), two key proteins that suppress immune responses in cancer. IO102-IO103 is currently in Phase 2 clinical trials for the treatment of melanoma and Phase 1 clinical trials for lung, head and neck, bladder, and other melanoma cancers. In addition to IO102-IO103, IO Biotech is also developing IO112, a product candidate targeting Arginase 1, another immunosuppressive enzyme found in various cancers. IO112 is designed to stimulate T cells that recognize epitopes derived from Arginase 1, further bolstering the immune response against tumors. The company's strategic focus on modulating the tumor microenvironment positions it within the rapidly evolving field of cancer immunotherapy, aiming to improve patient outcomes by enhancing the effectiveness of existing and emerging cancer treatments.
What Products and Services Does IOBT Offer?
- Develop immune-modulating cancer therapies.
- Utilize the T-win technology platform to target immunosuppressive proteins.
- Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
- Focus on improving patient outcomes in cancer treatment.
- Target the tumor microenvironment to enhance the body's immune response.
- Develop therapies to counteract the effects of IDO and PD-L1.
How Does IOBT Make Money?
- Develop and commercialize cancer immunotherapies.
- Generate revenue through potential future sales of approved products.
- Out-license or partner with larger pharmaceutical companies for commercialization.
- Secure funding through venture capital, public offerings, and strategic partnerships.
What Industry Does IOBT Operate In?
IO Biotech operates within the rapidly expanding biotechnology industry, specifically in the cancer immunotherapy market. This market is characterized by significant growth, driven by advances in understanding the tumor microenvironment and the development of novel therapeutic approaches. The competitive landscape includes major pharmaceutical companies and specialized biotech firms, all vying to develop more effective cancer treatments. IO Biotech's focus on modulating the tumor microenvironment through its T-win platform positions it within this competitive landscape, aiming to improve patient outcomes by enhancing the effectiveness of existing and emerging cancer treatments. The global cancer immunotherapy market is projected to reach billions of dollars in the coming years, reflecting the significant unmet need for innovative cancer therapies.
Who Are IOBT's Key Customers?
- Cancer patients
- Oncologists
- Hospitals and cancer centers
- Healthcare providers
IOBT Valuation & Market Position
With a 886K market cap, IO Biotech, Inc. sits in the micro-cap segment of the market. Relative to its peer group, IOBT's quantitative score of 49/100 is below the peer average of 78/100.
Net buyingInsider Activity
The most recent 12 insider filings for IO Biotech, Inc. break down as 0 sales and 12 purchases. On net that is roughly 1.4M shares acquired (about $1.6M) — insiders putting money in tends to read as conviction.
FY2026 estForward Outlook
Wall Street analysts project IO Biotech, Inc. revenue of about $13.9M for fiscal 2026, with EPS near $-0.29.
F-Score 1/9Financial Health
IO Biotech, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -21.30 places it in the distress zone, a signal of elevated financial risk.
IOBT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in IO Biotech's future, indicating that executives believe in the company's growth potential.
- Community sentiment has shifted positively, with discussions highlighting the promising results from recent clinical trials.
- Increased media coverage around innovative cancer treatments has boosted interest in IO Biotech's unique approach to immunotherapy.
- Analysts have noted the company's strong pipeline, which could lead to significant advancements in cancer therapies, attracting investor attention.
Bear Case
- Concerns about the competitive landscape in the biotech sector have emerged, with many companies racing to develop similar treatments.
- Recent volatility in the biotech market has led to cautious sentiment among investors, impacting IO Biotech's perceived stability.
- Some community members express skepticism about the long timeline for regulatory approvals, which could delay potential revenue streams.
- There are worries regarding funding and cash flow, as biotech firms often require substantial resources to bring products to market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
IOBT Latest News
No recent news available for IOBT.
IOBT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IOBT.
Price Targets
Consensus target: $0.50
IOBT MoonshotScore
What does this score mean?
The MoonshotScore rates IOBT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest IO Biotech, Inc. Analysis
Leadership: Mai-Britt Zocca
CEO
Mai-Britt Zocca serves as the Chief Executive Officer of IO Biotech, bringing extensive experience in the biopharmaceutical industry. Her background includes a strong foundation in clinical development and strategic leadership. Before joining IO Biotech, she held various leadership positions at pharmaceutical companies, focusing on the development and commercialization of innovative therapies. Her expertise spans across multiple therapeutic areas, including oncology and immunology. She has a proven track record of driving successful clinical programs and building high-performing teams.
Track Record: Under Mai-Britt Zocca's leadership, IO Biotech has advanced its lead product candidate, IO102-IO103, into Phase 2 clinical trials for melanoma and Phase 1 trials for other cancers. She has also overseen the development of IO112 and the expansion of the company's T-win technology platform. Her strategic decisions have positioned IO Biotech as a key player in the cancer immunotherapy market.
IOBT Healthcare Stock FAQ
What does IO Biotech, Inc. do?
IO Biotech, Inc. is a clinical-stage biopharmaceutical company specializing in the development of immune-modulating cancer therapies. The company's core technology, the T-win platform, is designed to target and neutralize immunosuppressive mechanisms within the tumor microenvironment, thereby enhancing the body's natural ability to fight cancer. Their lead product candidate, IO102-IO103, is a dual-target therapy designed to counteract the effects of Indoleamine 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1), two key proteins that suppress immune responses in cancer. IO Biotech aims to improve patient outcomes by developing innovative cancer treatments that harness the power of the immune system.
What do analysts say about IOBT stock?
As a clinical-stage biopharmaceutical company with a market cap of 886K, IO Biotech's valuation is primarily driven by the potential success of its clinical trials. Analyst consensus is heavily influenced by the progress and outcomes of these trials, particularly the Phase 2 trial for IO102-IO103 in melanoma. Key valuation metrics include the potential market size for its product candidates and the probability of regulatory approval. Growth considerations revolve around the expansion of IO102-IO103 into additional cancer indications and the advancement of IO112 through clinical development. The biotechnology sector is inherently risky, and analyst opinions can vary widely based on their assessment of these factors.
What are the main risks for IOBT?
IO Biotech faces several key risks inherent to the biotechnology industry. The primary risk is the potential failure of clinical trials for its product candidates, particularly IO102-IO103 and IO112. Clinical trial failures can result in significant financial losses and delays in product development. Regulatory hurdles and approval delays also pose a significant risk, as the company's success depends on obtaining regulatory approval for its products. Competition from established pharmaceutical companies with greater resources and expertise is another major risk. Additionally, changes in the healthcare landscape, such as reimbursement policies and treatment guidelines, could impact the commercial potential of IO Biotech's products.
What are the key factors to evaluate for IOBT?
IO Biotech, Inc. (IOBT) holds an AI score of 49/100 (low). Analysts target $0.50 (+3962%). Not financial advice.
How frequently does IOBT data refresh on this page?
IOBT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IOBT's recent stock price performance?
IO Biotech, Inc. (IOBT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel T-win technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IOBT overvalued or undervalued right now?
Valuing IO Biotech, Inc. (IOBT) requires multiple metrics. Analysts target $0.50 (+3962%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying IOBT?
Before investing in IO Biotech, Inc. (IOBT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- Clinical trial outcomes are inherently uncertain.